// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

Management of 1,25-dihydroxyvitamin D (1,25-OHD) Mediated Hypercalcemia of Unknown Etiology

Sruthi Menon - Endocrine Society (ENDO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Common variable immunodeficiency

Hydroxychloroquine

Importance of Immunosuppressive Therapy for Managing Insulin Resistance Type B

Samuel Amankwah - Endocrine Society (ENDO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Type 2 diabetes mellitus

Hydroxychloroquine

Novel Role of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts

Yan Guo - Endocrine Society (ENDO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Clinical risk stratification for hydroxychloroquine prescribing in a large urban district general hospital

A. Saravanan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

A NOVEL SCREENING METHOD FOR HYDROXYCHLOROQUINE MACULOPATHY

Hani Hasan - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

A PROSPECTIVE AUDIT OF A PATIENT COHORT PRESCRIBED HYDROXYCHLOROQUINE FOR RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY RHEUMATIC DISEASES IN ORDER TO PRIORITISE RETINOPATHY SCREENING AND ESTIMATE THE NEED FOR DRUG EDUCATION APPOINTMENTS

Brandon Yeo - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

A PROSPECTIVE STUDY OF TAPERING CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (C- DMARDS) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN STABLE REMISSION

SHAH ROMI - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

ACPA-POSITIVE RHEUMATOID ARTHRITIS PATIENTS BENEFITED MORE FROM ADVANCED TREATMENT STRATEGIES THAN ACPA-NEGATIVE RHEUMATOID ARTHRITISPATIENTS: 25-YEAR RESULTS OF A LONGITUDINAL COHORT STUDY

Xanthe Matthijssen - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

ADVERSE EVENTS AND THE RELAPSE RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS DURING HYDROXYCHLOROQUINE TREATMENT

Kunihiro Ichinose - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

ASSISTED REPRODUCTION TECHNIQUES: WHAT CAN WE TELL TO WOMEN WITH RHEUMATIC DISEASES?

Nathalie Costedoat-Chalumeau - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Lupus

Hydroxychloroquine

AUDIT ON HYDROXYCHLOROQUINE RELATED RETINOPATHY SCREENING IN RHEUMATOLOGY PATIENTS IN SVUH

Aadil Al Ghafri - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

CD4+CD25+FOXP3+ REGULATORY T CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: THE NEGATIVE ASSOCIATION WITH DISEASE ACTIVITY, ACUTE COURSE, TRANSITIONAL B CELLS AND IGG LEVELS

Elena Aleksandrova - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

CLINICAL EFFICACY OF LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY IN PRIMARY SJOGREN’S SYNDROME IS PREDICTED BY SERUM PROTEOME BIOMARKERS – RESULTS FROM REPURPSS-I

Joel van Roon - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

CURRENT PRACTICE OF HYDROXYCHLOROQUINE PRESCRIPTION AND MONITORING IN INDIA -A NATIONAL SURVEY

Shilpa Jagadeesh - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

DEVELOP A REPLICABLE MODEL FOR RATIONAL SELECTION OF STRATEGIES IN TREAT-TO-TARGET AND MAINTAIN-BEING-TARGET: REAL WORLD DATA MINING VIA SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)

Rong Mu - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

EFFECT OF IN VIVO HYDROXYCHLOROQUINE AND EX VIVO ANTI-BDCA2 TREATMENT ON PDC IFNα PRODUCTION FROM PATIENTS AFFECTED WITH CUTANEOUS LUPUS ERYTHEMATOSUS

Agnes Gardet - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

Hydroxychloroquine

EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJÖGREN’S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL

Alan Baer - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

EVALUATION OF ADHERENCE TO TREATMENT IN PATIENTS OF RHEUMATIC DISEASES

Svetlana Yakupova - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Rheumatoid arthritis

Hydroxychloroquine

EVALUATION OF THE IMPACT OF ROUTINE MONITORING OF BLOOD HYDROXYCHLOROQUINE LEVELS ON ADHERENCE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Farah Tamirou - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

EXPERIENCE IN THE USUAL PRACTICE OF PATIENTS WITH INFLAMMATORY MYOPATHIES AT THE DONOSTIA UNIVERSITY HOSPITAL

Jes�s Alejandro Valero Jaimes - European League Against Rheumatism (EULAR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved